

EFFECTIVENESS AND SAFETY OF PALBOCICLIB AND RIBOCICLIB

Alonso-Zazo F.J.¹, Moreno-García M.¹, Fernández-Fraga F.¹, Díez-Fernández R.¹, Molina-García T.¹
¹ Hospital Pharmacist. Pharmacy Department. Hospital Universitario de Getafe (Madrid). Spain

BACKGROUND AND IMPORTANCE



Several trials have demonstrated the benefit of anti-CDK4/6 inhibitors plus endocrine therapy in estrogen receptor-positive (ER+) advanced breast cancer (aBC), in first or subsequent lines of therapy. Based on clinical trials, palbociclib and ribociclib are equally effective in either first- or second-line therapy for advanced ER+ aBC, however, ported different toxicity profiles

AIM AND OBJECTIVES



To assess progression-free survival (PFS) and safety of palbociclib and ribociclib in real clinical practice

MATERIALS AND METHODS

- Observational
- Retrospective
- Descriptive

Palbociclib
Ribociclib


- Age
- Doses
- Adverse events
- Time to progression or death (PFS)
- Medical history

February 2018 to September 2020


RESULTS

42 PATIENTS

- 24 PALBOCICLIB (59.37±10.74 years)
- 18 RIBOCICLIB (58.94±11.79 years)



45.83% progressed (Palbociclib)
16.67% progressed (Ribociclib)



REDUCTION OF DOSES

PALBOCICLIB:
100% (125 mg)
→ 58,33% (100 mg) → 28,57% (75 mg)

✗ 72,22% neutropenia
✗ 16,67% gastrointestinal upset

RIBOCICLIB:
100% (600 mg)
→ 40% (400mg) → 28,57% (200 mg)

✗ 50% neutropenia
✗ 37,55% liver toxicity

CONCLUSIONS AND RELEVANCE

Comparing effectiveness, a greater PFS was found in ribociclib compared to palbociclib (2.09 months), there was a higher percentage of patients with progression in treatment with palbociclib (45.83% vs. 16.67 %)

Regarding toxicity, it was observed that ribociclib had a higher toxicity profile than palbociclib. Both required dose adjustment, greater in palbociclib, being neutropenia the main cause in both.

References:
 Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. Fausto Pretelli et al. PMID: 30659432
 Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Meritxell Ballet. PMID: 31205497

Email: falonsoz@salud.madrid.org
 Conflict of interest: nothing to disclose